The relationship between alternative medication possession ratio thresholds and outcomes: evidence from the use of glatiramer acetate

References

• Multiple Sclerosis International Federation. World of MS - About MS - Introduction. 2011. Available at: http://www.msif.org/en/about_ms/index.html. Accessed January 7, 2011
   Google Scholar
• Pugliatti M, Sotgiu S, Rosati G. The worldwide prevalence of multiple sclerosis. Clin Neurol Neurosurg 2002;104:182-91
   PubMed Web of Science ®Google Scholar
• National Multiple Sclerosis Society. Who gets MS?: National MS Society. 2011. Available at: http://www.nationalmssociety.org/about-multiple-sclerosis/what-we-know-about-ms/who-gets-ms/index.aspx. Accessed January 7, 2011
   Google Scholar
• Anderson DW, Ellenberg JH, Leventhal CM, et al. Revised estimate of the prevalence of multiple sclerosis in the United States. Ann Neurol 1992;31:333-6
   PubMed Web of Science ®Google Scholar
• Baum HM, Rothschild BB. The incidence and prevalence of reported multiple sclerosis. Ann Neurol 1981;10:420-8
   PubMed Web of Science ®Google Scholar
• Noonan CW, Kathman SJ, White MC. Prevalence estimates for MS in the United States and evidence of an increasing trend for women. Neurology 2002;58:136-8
   PubMed Web of Science ®Google Scholar
• Williamson DM, Henry JP. Challenges in addressing community concerns regarding clusters of multiple sclerosis and potential environmental exposures. Neuroepidemiology 2004;23:211-16
   Google Scholar
• Beretich BD, Beretich TM. Explaining multiple sclerosis prevalence by ultraviolet exposure: a geospatial analysis. Mult Scler 2009;15:891-8
   PubMed Web of Science ®Google Scholar
• Noonan CW, Williamson DM, Henry JP, et al. The prevalence of multiple sclerosis in 3 US communities. Prev Chronic Dis 2010;7:12. Available at: http://www.cdc.gov/pcd/issues/2010/jan/08_0241.htm. Accessed June 22, 2011
   PubMedGoogle Scholar
• Stuve O. Multiple Sclerosis Overview - GeneReviews - NCBI Bookshelf. 2010. Available at: http://www.ncbi.nlm.nih.gov/books/NBK1316/?log$=disease_name. Accessed January 7, 2011
   Google Scholar
• Alonso A, Hernán MA. Temporal trends in the incidence of multiple sclerosis: a systematic review. Neurology 2008;71:129-35
   PubMed Web of Science ®Google Scholar
• Asche CV, Singer ME, Jhaveri M, et al. All-cause health care utilization and costs associated with newly diagnosed multiple sclerosis in the United States. J Manag Care Pharm 2010;16: 703-12
   PubMedGoogle Scholar
• Kobelt G, Berg J, Atherly D, et al. Costs and quality of life in multiple sclerosis: a cross-sectional study in the United States. Neurology 2006;66:1696-702
   PubMed Web of Science ®Google Scholar
• Prescott JD, Factor S, Pill M, et al. Descriptive analysis of the direct medical costs of multiple sclerosis in 2004 using administrative claims in a large nationwide database. J Manag Care Pharm 2007;13:44-52. Available at: http://www.amcp.org/jmcphome.aspx. Accessed June 22, 2011
   PubMed Web of Science ®Google Scholar
• Jongen PJ, Lehnick D, Sanders E, et al. Health-related quality of life in relapsing remitting multiple sclerosis patients during treatment with glatiramer acetate: a prospective, observational, international, multi-centre study. Health Qual Life Outcomes 2010;8:133. Available at: http://www.hqlo.com/content/8/1/133. Accessed June 21, 2011
   PubMed Web of Science ®Google Scholar
• Mäurer M, Dachsel R, Domke S, et al. Health care situation of patients with relapsing-remitting multiple sclerosis receiving immunomodulatory therapy: a retrospective survey of more than 9000 German patients with MS. Eur J Neurol 2011; 18:1036-45
   PubMedGoogle Scholar
• National Multiple Sclerosis Society. Treatments: National MS Society. 2010. Available at: http://www.nationalmssociety.org/about-multiple-sclerosis/what-we-know-about-ms/treatments/index.aspx. Accessed January 7, 2011
   Google Scholar
• Ford C, Goodman AD, Johnson K, et al. Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetate. Mult Scler 2010;16:342-50
   PubMed Web of Science ®Google Scholar
• Ford CC, Johnson KP, Lisak RP, et al. A prospective open-label study of glatiramer acetate: over a decade of continuous use in multiple sclerosis patients. Mult Scler 2006;12:309-20
   PubMed Web of Science ®Google Scholar
• Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 1995;45:1268-76
   PubMed Web of Science ®Google Scholar
• Johnson KP, Brooks BR, Cohen JA, et al. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group. Neurology 1998;50:701-8
   PubMed Web of Science ®Google Scholar
• Johnson KP, Brooks BR, Ford CC, et al. Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 Multiple Sclerosis Study Group. Mult Scler 2000;6:255-66
   PubMed Web of Science ®Google Scholar
• Ge Y, Grossman RI, Udupa JK, et al. Glatiramer acetate (Copaxone) treatment in relapsing-remitting MS: quantitative MR assessment. Neurology 2000;54:813-7
   PubMed Web of Science ®Google Scholar
• Martinelli Boneschi F, Rovaris M, Johnson KP, et al. Effects of glatiramer acetate on relapse rate and accumulated disability in multiple sclerosis: meta-analysis of three double-blind, randomized, placebo-controlled clinical trials. Mult Scler 2003;9:349-55
   PubMed Web of Science ®Google Scholar
• Carter NJ, Keating GM. Glatiramer acetate: a review of its use in relapsing-remitting multiple sclerosis and in delaying the onset of clinically definite multiple sclerosis. Drugs 2010;70:1545-77
   PubMed Web of Science ®Google Scholar
• Mikol DD, Barkhof F, Chang P, et al. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapseing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing Disease [REGARD] study): a multicentre, randomised, parallel, open trial. Lancet Neurol 2008;7:903-14
   PubMed Web of Science ®Google Scholar
• O'Connor P, Filippa M, Arnason B, et al. 250 µg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol 2009;8:889-97.
   PubMed Web of Science ®Google Scholar
• Kleinman NL, Beren IA, Rajagopalan K, et al. Medication adherence with disease modifying treatments for multiple sclerosis among US employees. J Med Econ 2010;13:633-40
   PubMedGoogle Scholar
• Haas J, Firzlaff M. Twenty-four-month comparision of immunomodulatory treatments - a retrospective open label study in 308 RRMS patients treated with beta interferons or glatiramer acetate (Copaxone®). Eur J Neurol 2005;12:425-31
   PubMed Web of Science ®Google Scholar
• Castelli-Haley J, Oleen-Burkey M, Lage MJ, et al. Glatiramer acetate versus interferon beta-1a for subcutaneous administration: comparison of outcomes among multiple sclerosis patients. Adv Ther 2008;25:658-73
   PubMed Web of Science ®Google Scholar
• Castelli-Haley J, Oleen-Burkey MA, Lage MJ, et al. Glatiramer acetate and interferon beta-1b: a study of outcomes among patients with multiple sclerosis. Adv Ther 2009;26:552-62
   PubMed Web of Science ®Google Scholar
• Castelli-Haley J, Oleen-Burkey MA, Lage MJ, et al. Glatiramer acetate and interferon beta-1a for intramuscular administration: a study of outcomes among multiple sclerosis intent-to-treat and persistent-use cohorts. J Med Econ 2010;13:464-71
   PubMedGoogle Scholar
• World Health Organization. Adherence to long-term therapies: evidence for action. 2011. Available at: http://www.who.int/chp/knowledge/publications/adherence_report/en/index.html. Accessed February 7, 2011
   Google Scholar
• Halpern R, Agarwal S, Dembek C, et al. Comparison of adherence and persistence among multiple sclerosis patients treated with disease-modifying therapies: a retrospective administrative claims analysis. Patient Prefer Adherence 2011;5:73-84 Available at: http://dx.doi.org/10.2147/PPA.S15702. Accessed June 21, 2011
   PubMed Web of Science ®Google Scholar
• Tan H, Cai Q, Agarwal S, et al. Impact of adherence to disease-modifying thereapies on clinical and economic outcomes among patients with multiple sclerosis. Adv Ther 2011;28:51-61
   PubMed Web of Science ®Google Scholar
• Fraser C, Hadjimichael O, Vollmer T. Predictors of adherence to Copaxone therapy in individuals with relapsing-remitting multiple sclerosis. J Neurosci Nurs 2001;33:231-9
   PubMedGoogle Scholar
• Fraser C, Morgante L, Hadjimichael O, et al. A prospective study of adherence to glatiramer acetate in individuals with multiple sclerosis. J Neurosci Nurs 2004;36:120-9
   PubMedGoogle Scholar
• Zwibel H, Pardo G, Smith S, et al. A multicenter study of the predictors of adherence to self-injected glatiramer acetate for treatment of relapsing-remitting multiple sclerosis. J Neurol 2010;258:402-11
   PubMedGoogle Scholar
• Patti F. Optimizing the benefit of multiple sclerosis therapy: the importance of treatment adherence. Patient Prefer Adherence 2010;4:1-9. Available at: http://dx.doi.org/10.2147/PPA.S8230. Accessed June 21, 2011
   PubMed Web of Science ®Google Scholar
• Clerico M, Barbero P, Contessa G, et al. Adherence to interferon-beta treatment and results of therapy switching. J Neurol Sci 2007;259:104-8
   PubMed Web of Science ®Google Scholar
• Río J, Porcel J, Téllez N, et al. Factors related with treatment adherence to interferon beta and glatiramer acetate therapy in multiple sclerosis. Mult Scler 2005;11:306-9
   PubMed Web of Science ®Google Scholar
• Tremlett HL, Oger J. Interrupted therapy: stopping and switching of the beta-interferons prescribed for MS. Neurology 2003;61:551-4
   PubMed Web of Science ®Google Scholar
• International Society for Pharmacoeconomics and Outcomes Research. ISPOR medication compliance and persistence SIG accomplishments. 2011 Available at: http://www.ispor.org/sigs/mcp_accomplishments.asp. Accessed January 9, 2011
   Google Scholar
• Mattke S, Jain AK, Sloss EM, et al. Effect of disease management on prescription drug treatment: what is the right quality measure? Dis Manag 2007;10:91-100
   PubMedGoogle Scholar
• Cantrell CR, Eaddy MT, Shah MB, et al. Methods for evaluating patient adherence to antidepressant therapy: a real-world comparison of adherence and economic outcomes. Med Care 2006;44:300-3
   PubMed Web of Science ®Google Scholar
• Chastek BJ, Oleen-Burkey M, Lopez-Bresnahan MV. Medical chart validation of an algorithm for identifying multiple sclerosis relapse in healthcare claims. J Med Econ 2010;13:618-25 doi: 10.3111/13696998.2010.523670
   PubMedGoogle Scholar
• Cramer J, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health 2008;11:44-7. Available at: http://onlinelibrary.wiley.com/doi/10.1111/j.1524-4733.2007.00213.x/pdf. Accessed June 22, 2011
   PubMed Web of Science ®Google Scholar
• Chernew ME, Rosen AB, Fendrick AM. Value-based insurance design. Health Affairs 2007;26:w195-w203. Available at: http://content.healthaffairs.org/content/26/2/w195.full. Accessed June 22, 2011
   Web of Science ®Google Scholar
• Encinosa WE, Bernard D, Dor A. Does prescription drug adherence reduce hospitalizations and costs? The case of diabetes. Adv Health Econ Health Serv Res 2010;22:151-73
   PubMedGoogle Scholar
• Chesney M. Adherence to HAART regimens. AIDS Patient Care STDS 2003;17:169-77
   PubMed Web of Science ®Google Scholar
• Ickovics JR, Cameron A, Zackin R, et al. Consequences and determinants of adherence to antiretroviral medication: results from Adult AIDS Clinical Trials Group protocol 370. Antivir Ther (Lond) 2002;7:185-93
   PubMed Web of Science ®Google Scholar
• Valenti WM. Treatment adherence improves outcomes and manages costs. AIDS Read 2001;11:77-80
   PubMedGoogle Scholar
• Simpson RJ, Mendys P. The effects of adherence and persistence on clinical outcomes in patients treated with statins: a systematic review. J Clin Lipidol 2010;4:462-71
   PubMed Web of Science ®Google Scholar
• Whetten-Goldstein K, Sloan FA, Goldstein LB, et al. A comprehensive assessment of the cost of multiple sclerosis in the United States. Mult. Scler 1998;4:419-25
   PubMed Web of Science ®Google Scholar
• Baros AM, Latham PK, Moak DH, et al. What role does measuring medication compliance play in evaluating the efficacy of naltrexone? Alcohol Clin Exp Res 2007;31:596-603
   PubMed Web of Science ®Google Scholar
• Hansen R, Seifeldin R, Noe L. Medication adherence in chronic disease: issues in posttransplant immunosuppression. Transplant Proc 2007;39:1287-300
   PubMed Web of Science ®Google Scholar
• Nelson MR, Reid CM, Ryan P, et al. Self-reported adherence with medication and cardiovascular disease outcomes in the Second Australian National Blood Pressure Study (ANBP2). Med J Aust 2006;185:487–9. Available at: http://www.mja.com.au/public/issues/185_09_061106/contents_061106.html. Accessed June 22, 2011
   Google Scholar
• Schectman JM, Nadkarni MM, Voss JD. The association between diabetes metabolic control and drug adherence in an indigent population. Diabetes Care 2002;25:1015–21. Available at: http://care.diabetesjournals.org/content/25/6/1015.full.pdf+html. Accessed June 22, 2011
   Google Scholar
• Svarstad BL, Shireman TI, Sweeney JK. Using drug claims data to assess the relationship of medication adherence with hospitalization and costs. Psychiatr Serv 2001;52:805–11. Available at: http://psychservices.psychiatryonline.org/cgi/content/full/52/6/805. Accessed June 22, 2011
   Google Scholar